Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090)
Publication
, Journal Article
Herrington, WG; Preiss, D; Haynes, R; von Eynatten, M; Staplin, N; Hauske, SJ; George, JT; Green, JB; Landray, MJ; Baigent, C; Wanner, C
Published in: Clinical Kidney Journal
January 1, 2020
In the footnote of Figure 5 “Empagliflozin 0/4687 vs placebo 1/2333 participant reported Fournier's gangrene (perineal necrotizing fasciitis)” has been replaced with “Empagliflozin 0/4687 vs placebo 0/2333 participants reported Fournier's gangrene (perineal necrotizing fasciitis)”.
Duke Scholars
Published In
Clinical Kidney Journal
DOI
EISSN
2048-8513
ISSN
2048-8505
Publication Date
January 1, 2020
Volume
13
Issue
4
Start / End Page
722
Related Subject Headings
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., … Wanner, C. (2020). Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090). Clinical Kidney Journal, 13(4), 722. https://doi.org/10.1093/CKJ/SFZ009
Herrington, W. G., D. Preiss, R. Haynes, M. von Eynatten, N. Staplin, S. J. Hauske, J. T. George, et al. “Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090).” Clinical Kidney Journal 13, no. 4 (January 1, 2020): 722. https://doi.org/10.1093/CKJ/SFZ009.
Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, et al. Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090). Clinical Kidney Journal. 2020 Jan 1;13(4):722.
Herrington, W. G., et al. “Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090).” Clinical Kidney Journal, vol. 13, no. 4, Jan. 2020, p. 722. Scopus, doi:10.1093/CKJ/SFZ009.
Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C. Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090). Clinical Kidney Journal. 2020 Jan 1;13(4):722.
Published In
Clinical Kidney Journal
DOI
EISSN
2048-8513
ISSN
2048-8505
Publication Date
January 1, 2020
Volume
13
Issue
4
Start / End Page
722
Related Subject Headings
- 3202 Clinical sciences